Wall Street brokerages expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will post ($0.46) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.15). Intellia Therapeutics posted earnings of ($0.44) per share in the same quarter last year, which would suggest a negative year over year growth rate of 4.5%. The business is scheduled to issue its next quarterly earnings report on Tuesday, October 30th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($2.25) to ($1.56). For the next financial year, analysts forecast that the business will report earnings of ($2.52) per share, with EPS estimates ranging from ($3.15) to ($1.94). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. The business had revenue of $7.68 million during the quarter, compared to analyst estimates of $6.39 million. Intellia Therapeutics had a negative net margin of 284.56% and a negative return on equity of 31.54%. The company’s quarterly revenue was up 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.45) EPS.
NASDAQ:NTLA traded up $0.64 during trading hours on Friday, hitting $28.13. 6,866 shares of the company were exchanged, compared to its average volume of 674,131. The company has a market cap of $1.22 billion, a PE ratio of -15.05 and a beta of 2.93. Intellia Therapeutics has a 52-week low of $15.06 and a 52-week high of $35.99.
In related news, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $25.04, for a total transaction of $167,417.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John M. Leonard sold 8,400 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The disclosure for this sale can be found here. Insiders have sold 28,458 shares of company stock worth $764,361 over the last three months. 12.80% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in shares of Intellia Therapeutics by 108.0% in the fourth quarter. Wells Fargo & Company MN now owns 34,767 shares of the company’s stock valued at $668,000 after buying an additional 18,050 shares during the last quarter. BlackRock Inc. raised its position in shares of Intellia Therapeutics by 1.9% in the fourth quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Intellia Therapeutics by 42.5% in the fourth quarter. Geode Capital Management LLC now owns 195,925 shares of the company’s stock valued at $3,765,000 after buying an additional 58,411 shares during the last quarter. Deutsche Bank AG raised its position in shares of Intellia Therapeutics by 8.5% in the fourth quarter. Deutsche Bank AG now owns 41,744 shares of the company’s stock valued at $800,000 after buying an additional 3,279 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Intellia Therapeutics by 306.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 129,900 shares of the company’s stock valued at $2,497,000 after buying an additional 97,936 shares during the last quarter. Institutional investors own 59.81% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Article: Trading Strategy Methods and Types
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.